Aclarion, Inc.
Nasdaq · Services-Medical Laboratories
Company Overview
A concise company profile alongside the latest public filing activity.
Aclarion develops Nociscan, an AI-powered diagnostic technology that uses magnetic resonance spectroscopy to identify chemical markers of pain in spinal discs, helping physicians determine whether a patient's back pain is likely to respond to surgery. The company markets its analysis platform to spine surgeons and imaging centers to support treatment planning decisions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Williams Amanda MDirector | Buy | $16K | 5,857at $2.73 | Aug 17, 2026 |
| Gould Gregory ACFO | Buy | $25K | 10,000at $2.45 | Aug 14, 2026 |
| Bond RyanDirector | Buy | $50K | 21,122at $2.37 | Aug 13, 2026 |
| Neal David KDirector | Buy | $18K | 7,500at $2.40 | Aug 13, 2026 |
| Ness BrentChief Executive Officer | Buy | $12K | 5,234at $2.31 | Aug 13, 2026 |
| Wesemann WilliamDirector | Buy | $5K | 2,150at $2.34 | Aug 13, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ACON activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.